Ewing sarcoma: historical perspectives, current state-of-the-art, and opportunities for targeted therapy in the future, Current Opinion in Oncology, vol.20, issue.4, pp.412-420, 2008. ,
DOI : 10.1097/CCO.0b013e328303ba1d
Ewing sarcoma treatment, European Journal of Cancer, vol.47, pp.366-367, 2011. ,
DOI : 10.1016/S0959-8049(11)70206-4
Principles and practice of paediatric oncology, Wolters Kluwer, 2010. ,
Prognostic factors for survival in patients with Ewing's sarcoma using the surveillance, epidemiology, and end results (SEER) program database, Cancer Epidemiology, vol.39, issue.2, pp.189-95, 2015. ,
DOI : 10.1016/j.canep.2014.12.012
Changes in Incidence and Survival of Ewing Sarcoma Patients Over the Past 3 Decades, Journal of Pediatric Hematology/Oncology, vol.30, issue.6, pp.425-455, 2008. ,
DOI : 10.1097/MPH.0b013e31816e22f3
Primary Disseminated Multifocal Ewing Sarcoma: Results of the Euro-EWING 99 Trial, Journal of Clinical Oncology, vol.28, issue.20, pp.3284-3291, 2010. ,
DOI : 10.1200/JCO.2009.22.9864
Prognostic factors for local and distant control in Ewing sarcoma family of tumors, Annals of Oncology, vol.19, issue.4, pp.814-834, 2008. ,
DOI : 10.1093/annonc/mdm521
Results of the EICESS-92 Study: Two Randomized Trials of Ewing's Sarcoma Treatment???Cyclophosphamide Compared With Ifosfamide in Standard-Risk Patients and Assessment of Benefit of Etoposide Added to Standard Treatment in High-Risk Patients, Journal of Clinical Oncology, vol.26, issue.27, pp.4385-4393, 2008. ,
DOI : 10.1200/JCO.2008.16.5720
Prognostic Factors in Localized Ewing's Tumours and Peripheral NeuroectodermalTumours: The Third Study of the French Society of Paediatric Oncology (EW88 Study), British Journal of Cancer, vol.85, pp.11-1646, 2001. ,
Prognostic Factors in Nonmetastatic Ewing???s Sarcoma of Bone Treated With Adjuvant Chemotherapy: Analysis of 359 Patients at the Istituto Ortopedico Rizzoli, Journal of Clinical Oncology, vol.18, issue.1, pp.4-11, 2000. ,
DOI : 10.1200/JCO.2000.18.1.4
Diagnostic accuracy of 18???F-FDG-PET and PET/CT in patients with Ewing sarcoma family tumours: a systematic review and a meta-analysis, Skeletal Radiology, vol.49, issue.3, pp.249-56, 2012. ,
DOI : 10.3413/nukmed-03131004
-glucose positron emission tomography, bone scan, and bone marrow aspiration/biopsy as staging investigations in Ewing Sarcoma, Pediatric Blood & Cancer, vol.54, issue.7, pp.1113-1120, 2013. ,
DOI : 10.1002/pbc.22245
Diagnostic accuracy of 18F-FDG PET/CT for detecting recurrence in patients with primary skeletal Ewing sarcoma, European Journal of Nuclear Medicine and Molecular Imaging, vol.59, issue.Suppl, pp.1036-1079, 2013. ,
DOI : 10.1002/pbc.24242
Positron Emission Tomography for Staging of Pediatric Sarcoma Patients: Results of a Prospective Multicenter Trial, Journal of Clinical Oncology, vol.25, issue.34, pp.5435-5476, 2007. ,
DOI : 10.1200/JCO.2007.12.2473
FDG???PET for detection of recurrences from malignant primary bone tumors: comparison with conventional imaging, Annals of Oncology, vol.13, issue.1, pp.157-60, 2002. ,
DOI : 10.1093/annonc/mdf012
Impact of FDG PET for staging of Ewing sarcomas and primitive neuroectodermal tumours, Nuclear Medicine Communications, vol.27, issue.1, pp.17-24, 2006. ,
DOI : 10.1097/01.mnm.0000186608.12895.69
The importance of PET/CT in the evaluation of patients with Ewing tumors, Radiologia Brasileira, vol.187, issue.15S, pp.175-180, 2015. ,
DOI : 10.2214/AJR.06.0171
F]Fluorodeoxyglucose Positron Emission Tomography Predicts Outcome for Ewing Sarcoma Family of Tumors, Journal of Clinical Oncology, vol.23, issue.34, pp.8828-8862, 2005. ,
DOI : 10.1200/JCO.2005.01.7079
Response to chemotherapy estimates by FDG PET is an important prognostic factor in patients with Ewing sarcoma, Clinical and Translational Oncology, vol.27, issue.8, pp.18-189, 2016. ,
DOI : 10.1097/01.mnm.0000237986.31597.86
Potential Role of FDG PET Imaging in Predicting Metastatic Potential and Assessment of Therapeutic Response to Neoadjuvant Chemotherapy in Ewing Sarcoma Family of Tumors, Clinical Nuclear Medicine, vol.36, issue.11, pp.973-980, 2011. ,
DOI : 10.1097/RLU.0b013e31822f684b
18F-FDG PET response to neoadjuvant chemotherapy for Ewing sarcoma and osteosarcoma are different, Skeletal Radiology, vol.59, issue.2, pp.1007-1022, 2011. ,
DOI : 10.1002/1097-0142(19870115)59:2<252::AID-CNCR2820590213>3.0.CO;2-P
Prognostic Value of SUVmax Measured by Pretreatment Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Patients with Ewing Sarcoma, PLOS ONE, vol.2, issue.1 ,
DOI : 10.1371/journal.pone.0153281.s002
Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial, Pediatric Blood & Cancer, vol.22, issue.1, pp.22-29, 2006. ,
DOI : 10.1002/pbc.20820
Cyclophosphamide Compared With Ifosfamide in Consolidation Treatment of Standard-Risk Ewing Sarcoma: Results of the Randomized Noninferiority Euro-EWING99-R1 Trial, Journal of Clinical Oncology, vol.32, issue.23, pp.2440-2448, 2014. ,
DOI : 10.1200/JCO.2013.54.4833
The Maximum Standardized Uptake Values on Integrated FDG-PET/CT Is Useful in Differentiating Benign From Malignant Pulmonary Nodules, The Annals of Thoracic Surgery, vol.82, issue.3, pp.1016-1036, 2006. ,
DOI : 10.1016/j.athoracsur.2006.03.095
Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding, Cancer, vol.34, issue.S12, pp.2505-2514, 1997. ,
DOI : 10.1117/12.967025
Prognostic significance of 18F-FDG PET at diagnosis in patients with soft tissue sarcoma and bone sarcoma; systematic review and meta-analysis, European Journal of Cancer, vol.58, pp.104-115, 2016. ,
DOI : 10.1016/j.ejca.2016.02.007
Analysis of prognostic factors in Ewing sarcoma using a population-based cancer registry, Cancer, vol.11, issue.8, pp.1964-73, 2010. ,
DOI : 10.1002/cncr.22821
Prognostic factors for overall survival in paediatric patients with Ewing sarcoma of bone treated according to multidisciplinary protocol, Clinical and Translational Oncology, vol.15, issue.[Suppl1], pp.294-301, 2012. ,
DOI : 10.1007/BF00263897
Comparative Assessment of Methods for Estimating Tumor Volume and Standardized Uptake Value in 18F-FDG PET, Journal of Nuclear Medicine, vol.51, issue.2, pp.268-76, 2010. ,
DOI : 10.2967/jnumed.109.066241
URL : https://hal.archives-ouvertes.fr/inserm-00466261
Impact of the Definition of Peak Standardized Uptake Value on Quantification of Treatment Response, Journal of Nuclear Medicine, vol.53, issue.1, pp.4-11, 2012. ,
DOI : 10.2967/jnumed.111.093443
The age of reason for FDG PET image-derived indices, European Journal of Nuclear Medicine and Molecular Imaging, vol.25, issue.3, pp.1670-72, 2012. ,
DOI : 10.1038/nbt1306
URL : https://hal.archives-ouvertes.fr/inserm-00733622
Pre-therapy 18F-FDG PET quantitative parameters help in predicting the response to radioimmunotherapy in non-Hodgkin lymphoma, European Journal of Nuclear Medicine and Molecular Imaging, vol.29, issue.suppl, pp.494-504, 2010. ,
DOI : 10.1007/s00259-003-1166-5
Baseline 18F-FDG PET image-derived parameters for therapy response prediction in oesophageal cancer, European Journal of Nuclear Medicine and Molecular Imaging, vol.17, issue.1, pp.1595-1606, 2011. ,
DOI : 10.1245/s10434-009-0719-7
URL : https://hal.archives-ouvertes.fr/inserm-00595534
Prognostic value of quantitative fluorodeoxyglucose measurements in newly diagnosed metastatic breast cancer, Cancer Medicine, vol.10, issue.Suppl. 1, pp.725-733, 2013. ,
DOI : 10.1517/14656560902834961
Prognostic value of volumetric parameters of 18F-FDG PET in non-small-cell lung cancer: a meta-analysis, European Journal of Nuclear Medicine and Molecular Imaging, vol.285, issue.7, pp.241-51, 2014. ,
DOI : 10.1097/MNM.0b013e3283599999
Prognostic value of 18F-FDG PET image-based parameters in oesophageal cancer and impact of tumour delineation methodology, European Journal of Nuclear Medicine and Molecular Imaging, vol.51, issue.9, pp.1191-1202, 2011. ,
DOI : 10.2967/jnumed.110.078501
URL : https://hal.archives-ouvertes.fr/inserm-00574267
SUVref: reducing reconstruction-dependent variation in PET SUV, EJNMMI Research, vol.1, issue.1, p.16, 2011. ,
DOI : 10.2967/jnumed.109.063016